Bisphosphonates for controlling pain from metastatic bone disease

American Journal of Health-System Pharmacy

Volumn 53, Issue 16, 1996, Pages 1917-1927

  Diener, Kathy M ^a,b  

^a UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Alendronate sodium; Bisphosphonates; Calcium regulators; Clodronate disodium; Etidronate disodium; Neoplasm metastasis; Pain; Pamidronate disodium; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ANTACID AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; FOSCARNET SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; RANITIDINE; STRONTIUM 89;

BONE MARROW TOXICITY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PATIENT EDUCATION; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0029796945     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.16.1917     Document Type: Review

References (67)

1. Cleeland CS, Gonin R, Hatfield AK et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med. 1994; 330:592-6.
2. Von Roenn JH, Cleeland CS, Gonin R et al. Physician attitudes and practice in cancer pain management: a survey from the Eastern Cooperative Oncology Group. Ann Intern Med. 1993; 119:121-6.
3. Scher HI, Yagoda A. Bone metastases: pathogenesis, treatment and rationale for use of resorption inhibitors. Am J Med. 1987; 82:6-28.
4. Abrams HL, Spiro R, Goldstein N. Metastasis in carcinoma: analysis of 1000 autopsied cases. Cancer. 1950; 3:74-85.
5. Lote K, Walloe A, Bjersand A. Bone metastasis: prognosis, diagnosis and treatment. Acta Radiol Oncol. 1986; 25:227-32.
6. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991; 9:509-24.
7. Gilbert HA, Kagan AR, Nussbaum H et al. Evaluation of radiation therapy for bone metastases: pain relief and quality of life. Am J Roentgenol. 1977; 129:1095-6.
8. Bagshaw MA, Kaplan ID, Valdagni R et al. Radiation treatment of prostate bone metastases and the biological considerations. In: Karr JP, Yamanaka H, eds. Prostate cancer and bone metastasis. New York: Plenum; 1992:255-68.
9. 89strontium therapy in patients with carcinoma of the prostate and incurable pain from bone metastases: a preliminary report. J Urol. 1976; 116:764-8.
10. Serafini AN. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys. 1994; 30:1187-94.
11. Porter AT. Use of strontium-89 in metastatic cancer: US and UK experience. Oncology. 1994; 11S:25-9.
12. Asbury RF, Bakemeier RF, Folsch E et al. Treatment of metastatic breast cancer with aminoglutethimide. Cancer. 1981; 47:1954-8.
13. Elomaa I, Taube T, Blomqvist C et al. Aminoglutethimide for advanced prostatic cancer resistant to conventional hormonal therapy. Eur Urol. 1988; 14:104-6.
14. Serdengecti S, Serdengecti K, Derman R et al. Salmon calcitonin in the treatment of bone metastases. Int J Clin Pharmacol Res. 1986; 6:151-5.
15. Hindley AC, Hill EB, Leyland MJ et al. A double-blind controlled trial of salmon calcitonin in pain due to malignancy. Cancer Chemother Pharmacol. 1982; 9:71-4.
16. Weissman D, Smith R. Phase II evaluation of intranasal calcitonin for relief of cancer pain from bone metastases. Proc Annu Meet Am Soc Clin Oncol. 1988; 7:1009. Abstract.
17. Averbuch SD. New bisphosphonates in the treatment of bone metastases. Cancer. 1993; 72S:3443-52.
18. Liotta LA, Stetler-Stevenson WG. Principles of molecular cell biology of cancer: cancer metastasis. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: Lippincott; 1989:98-115.
19. Manishen WJ, Sivananthan K, Orr FW. Resorbing bone stimulates tumor cell growth: a role for the host microenvironment in bone metastasis. Am J Pathol. 1986; 123:39-45.
20. Coleman RE, Purohit OP. Osteoclast inhibition for the treatment of bone metastases. Cancer Treat Rev. 1993; 19:79-103.
21. Dodwell DJ. Malignant bone resorption: cellular and biochemical mechanisms. Ann Oncol. 1992; 3:257-67.
22. Christen C. Treatment of hypercalcemia of malignancy. Mich Drug Lett. 1988; 7(9).
23. McCauley DL. Update in the management of hypercalcemia of malignancy. Mich Drug Lett. 1994; 13(2).
24. Warrell RP. Metabolic emergencies. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology. Philadelphia: Lippincott; 1993:2128-41.
25. Fleisch H. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res. 1989; 116:1-28.
26. Fitton A, McTavish D. Pamidionate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone diseases. Drugs. 1991; 41:289-318.
27. Plosker GL, Goa KL. Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 1994; 47:945-82.
28. Russell RGG, Fleisch H. Pyrophosphate and diphosphonates in skeletal metabolism. Clin Orthop. 1975; 108:241-67.
29. Fogelman I, Smith L, Mazess R et al. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol. 1986; 24:57-62.
30. Smith JA Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol. 1989; 141:85-7.
31. Schnur W. Etidronate for the relief of metastatic bone pain. J Urol. 1984; 131:209A. Abstract.
32. Carey PO, Lippert MC. Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology. 1988; 32:403-7.
33. Plosker GL, Goa KL. Clodronate: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs. 1994; 47:945-82.
34. Yakatan GJ, Poynor WJ, Talbert RL et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther. 1982; 31:402-10.
35. Pentikainen PJ, Elomaa I, Nurmi AK et al. Pharmacokinetics of clodronate in patients with metastatic breast cancer. Int J Clin Pharmacol Ther Toxicol. 1989; 27:222-8.
36. Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res. 1989; 116:67-78.
37. Vorreuther R. Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol. 1993; 72:792-5.
38. Ernst DS, Brasher P, Hagen N et al. Randomized, controlled trial of intravenous clodronate in patients with painful bone metastases. Proc Annu Meet Am Soc Clin Oncol. 1993; 12:1563. Abstract.
39. Ernst DS, Brasher P, Hagen N et al. Controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. Proc Annu Meet Am Soc Clin Oncol. 1994; 13:1478. Abstract.
40. Paterson AHG, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993; 11:59-65.
41. Tubiana-Hulin M, Beuzeboc P, Mauriac L et al. Double blind placebo controlled trial of oral clodronate in patients with bone metastases from breast cancer. Effect on induced hyperosteolysis. Proc Annu Meet Am Soc Clin Oncol. 1995; 14:1718. Abstract.
42. Elomaa I, Kylmala T, Tammela T et al. Effect of oral clodronate on bone pain: a controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol. 1992; 24:159-66.
43. Lahtinen R, Laakso M, Palva I et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet. 1992; 340:1049-52.
44. O'Rourke N, McCloskey E, Houghton F et al. Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases. J Clin Oncol. 1995; 13:929-34.
45. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol. 1995; 13:2427-30.
46. Gertz BM, Holland SD, Kline WF et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther. 1995; 58:288-98.
47. Attardo-Parrinello G, Giampaolo M, Pavesi F et al. Effects of a new aminodiphosphonate (aminohydroxybutylidene diphosphonate) in patients with osteolytic lesions from metastases and myelomatosis: comparison with dichloromethylene diphosphonate. Arch Intern Med. 1987; 157:1629-33.
48. Dodwell D, Howell A, Morton AR et al. Biochemical effects, antitumor activity and pharmacokinetics of oral and IV pamidronate in the treatment of skeletal breast cancer. Br J Cancer. 1990; 62:1990. Abstract.
49. VanHolten-Verzantvoort AT, Bijvoet OLM, Cleton FJ et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet. 1987; 2:983-5.
50. VanHolten-Verzantvoort AT, Kroon HM, Bijvoet OLM et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol. 1993; 11:491-8.
51. Latreille J, Conte PJ, Mauriac L et al. Aredia infusions in breast cancer: a randomized Phase III trial to assess delay in progression of bone metastases. Proc Annu Meet Am Soc Clin Oncol. 1994; 13:78. Abstract.
52. Conte PF, Gianesse PG, Latreille J et al. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter Phase III trial. Ann Oncol. 1994; 5S7:41S-4S.
53. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996; 332:488-93.
54. Tyrrell CJ. Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multicenter Phase II trial. Ann Oncol. 1994; 5S7:37S-40S.
55. Clarke NW, Holbrook IB, McClure J et al. Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study. Br J Cancer. 1991; 63:420-3.
56. Lipton A, Glover D, Grabelsky S et al. Pamidronate disodium (APD) - a dose-seeking study in patients with prostate cancer. Proc Annu Meet Am Soc Clin Oncol. 1991; 10:564. Abstract.
57. Thürlimann B, Weisser F, Radziwill A et al. Pamidronate in patients with malignant osteolytic bone disease and pain: a prospective randomized dose finding study. Proc Annu Meet Am Soc Clin Oncol. 1993; 12:1488. Abstract.
58. Howe D, Pevnick W, Partridge H et al. Pamidronate: relief of bone pain in metastatic cancer. Proc Annu Meet Am Soc Clin Oncol. 1993; 12:1623. Abstract.
59. Purohit OP, Anthony C, Radstone CR et al. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer. 1994; 70:554-8.
60. Glover D, Lipton A, Keller A et al. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. Cancer. 1994; 74:2949-55.
61. Didronel package insert. Minneapolis: MGI Pharma; 1994 Jul.
62. Aredia package insert. Summit, NJ: Ciba-Geigy; 1994 Sep.
63. Liberman UA, Weiss SR, Bröll J et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 1995; 333:1437-43.
64. Mian M, Beghe F, Caprio A et al. Tolerability and safety of clodronate therapy in bone diseases. Int J Clin Pharmacol Res. 1991; 11:107-1.
65. Fosamax package insert. West Point, PA: Merck & Co.; 1995 Sep.
66. Gucalp R, Theriault R, Gill I et al. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med. 1994; 154:1935-44.
67. Red book. Montvale, NJ: Medical Economics Data Production; 1996.